William H. Frishman

Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism

Obesity remains a major modifiable driver of cardiovascular disease. Emerging antiobesity pharmacotherapies demonstrate substantial weight loss alongside improvements in multiple cardiometabolic parameters. This literature review summarizes the early clinical studies of eloralint...